CN105555266B - 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品 - Google Patents

用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品 Download PDF

Info

Publication number
CN105555266B
CN105555266B CN201480050770.5A CN201480050770A CN105555266B CN 105555266 B CN105555266 B CN 105555266B CN 201480050770 A CN201480050770 A CN 201480050770A CN 105555266 B CN105555266 B CN 105555266B
Authority
CN
China
Prior art keywords
hcv
interferon
ns5a
compound
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480050770.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105555266A (zh
Inventor
A·X·王
O·D·洛佩兹
Y·涂
M·贝莱马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN105555266A publication Critical patent/CN105555266A/zh
Application granted granted Critical
Publication of CN105555266B publication Critical patent/CN105555266B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480050770.5A 2013-07-17 2014-07-15 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品 Expired - Fee Related CN105555266B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847388P 2013-07-17 2013-07-17
US61/847,388 2013-07-17
PCT/US2014/046685 WO2015026454A1 (en) 2013-07-17 2014-07-15 Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus

Publications (2)

Publication Number Publication Date
CN105555266A CN105555266A (zh) 2016-05-04
CN105555266B true CN105555266B (zh) 2018-11-30

Family

ID=51293156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480050770.5A Expired - Fee Related CN105555266B (zh) 2013-07-17 2014-07-15 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品

Country Status (4)

Country Link
EP (1) EP3021846A1 (https=)
JP (1) JP2016525114A (https=)
CN (1) CN105555266B (https=)
WO (1) WO2015026454A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017076187A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
WO2017076194A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 具有抑制hcv活性的化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
CN102480971A (zh) * 2009-09-04 2012-05-30 葛兰素史密丝克莱恩有限责任公司 化合物
CN102655873A (zh) * 2009-10-12 2012-09-05 百时美施贵宝公司 特异性hcv ns5a抑制剂与hcv ns3蛋白酶抑制剂的组合
WO2012166716A2 (en) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9326973B2 (en) * 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102480971A (zh) * 2009-09-04 2012-05-30 葛兰素史密丝克莱恩有限责任公司 化合物
CN102655873A (zh) * 2009-10-12 2012-09-05 百时美施贵宝公司 特异性hcv ns5a抑制剂与hcv ns3蛋白酶抑制剂的组合
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
WO2012166716A2 (en) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Also Published As

Publication number Publication date
EP3021846A1 (en) 2016-05-25
CN105555266A (zh) 2016-05-04
JP2016525114A (ja) 2016-08-22
WO2015026454A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AU2021286264B2 (en) Use of inhibitors of Bruton's tyrosine kinase (Btk)
CA3154024C (en) Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
CN103492381A (zh) 流感病毒复制的抑制剂
CA3183081A1 (en) Combination therapy for treatment of cancer
JP2017101086A (ja) Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
MX2015003513A (es) Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion.
CN105503862A (zh) 流感病毒复制抑制剂
CN101977915A (zh) 大环丝氨酸蛋白酶抑制剂
US20180194762A1 (en) PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE
CN105555266B (zh) 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品
US20240262795A1 (en) Pyrazine compounds as inhibitors of flt3
JP2024511466A (ja) Ａｌｋ－５阻害剤及びその使用
CN103421068A (zh) 具有抗病毒活性的杂芳基磷酰胺类化合物
CN105530933B (zh) 用于治疗hcv的包含联苯衍生物的组合产品
EP3050871A1 (en) Novel bis-amide derivative and use thereof
JP2023507188A (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
TW202019927A (zh) 流感病毒複製之抑制劑
CA3229937A1 (en) Pyrazine compounds as irreversible inhibitors of flt3
AU2024266757A1 (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)
CN118829631A (zh) 作为flt3抑制剂的吡嗪类化合物
CN110117287A (zh) 作为丙型肝炎病毒抑制剂的盐
CA3090493A1 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
NZ617102B2 (en) Substituted aliphanes, cyclophanes, heteraphanes, heterophanes and hetero-heteraphanes useful for treating hcv infections
NZ755485B2 (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181130

Termination date: 20200715

CF01 Termination of patent right due to non-payment of annual fee